The UK equity release market: Views from the regulatory authorities, product providers and advisors

This study investigates the factors constraining the development of the UK equity release market. The results of a thematic review of interviews with industry stakeholders (product providers, advice providers and regulators) suggest that the attractiveness of the equity market for insurance companies (the main funders of the market), has diminished following a decline in annuity business and complications around the capital maturity matching requirements under Solvency II. Product costs (interest charges, and the cost of financial advice) are high. Trust in the market has improved, but remains fragile. Increased entry into the market by recognised brand names, (such as the traditional mortgage providers) would increase competition, reduce costs and promote trust. The risk of reputational damage limits the appeal of the market to new entrants. The no negative equity guarantee, a cost in terms of lower than otherwise loan-to-value ratios, promotes demand by way of the protection it affords to customers and their beneficiaries. Equity release is unsuitable for funding long-term care and policymakers advocating it as such damage the market.

Automated summary

This study investigates the factors constraining the development of the UK equity release market. The findings suggest that the attractiveness of the market for insurance companies has decreased due to a decline in annuity business and complications around regulatory requirements. High costs and fragile trust in the market are also identified. Entry of recognized brand names would increase competition and trust, but the risk of reputational damage limits new entrants. The no negative equity guarantee promotes demand, but policymakers advocating for inappropriate use of equity release damage the market.